Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Success fee to Bioinvent and partner

The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.

Future drugs from Amaryllis

A Danish research team has discovered possibolities to extract drugs fro Amaryllis.

New map of eye proteins

A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.

LEO Pharma - International Clinical Trial Manager

Parnevik firm in Swiss osteoporosis deal

The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

Danish focus on bio chemicals

The Danish company Genencor and the German company BRAIN establish a research collaboration for the production of biobased chemicals from renewable feedstock.

New tools to fight bacteria

Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antibiotic-resistant bacteria. That is stated in a report commissioned by the Swedish government.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.